A Phase 1/2a Randomized, Double-masked, Placebo Controlled, Dose-ranging Study of the Safety and Efficacy of H-1337 in Subjects With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension
Phase of Trial: Phase I/II
Latest Information Update: 10 Sep 2018
Price : $35 *
At a glance
- Drugs H-1337 (Primary)
- Indications Ocular hypertension; Open-angle glaucoma
- Focus Therapeutic Use
- Sponsors Allysta Pharmaceuticals
- 30 Aug 2018 Status changed from recruiting to completed.
- 19 Mar 2018 Status changed from not yet recruiting to recruiting.
- 07 Mar 2018 New trial record